UCB SA (UCB.BR)
EUR 169.35
(-0.03%)
EUR 169.35
(-0.03%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.34 Billion EUR | -8.54% |
| 2022 | 3.65 Billion EUR | -12.27% |
| 2021 | 4.16 Billion EUR | 9.35% |
| 2020 | 3.8 Billion EUR | 9.27% |
| 2019 | 3.48 Billion EUR | 1.51% |
| 2018 | 3.43 Billion EUR | 4.89% |
| 2017 | 3.27 Billion EUR | 11.17% |
| 2016 | 2.94 Billion EUR | 8.31% |
| 2015 | 2.71 Billion EUR | 18.68% |
| 2014 | 2.29 Billion EUR | 5.67% |
| 2013 | 2.16 Billion EUR | -8.83% |
| 2012 | 2.37 Billion EUR | 6.49% |
| 2011 | 2.23 Billion EUR | 3.14% |
| 2010 | 2.16 Billion EUR | 3.54% |
| 2009 | 2.09 Billion EUR | -14.83% |
| 2008 | 2.45 Billion EUR | -4.81% |
| 2007 | 2.57 Billion EUR | 30.12% |
| 2006 | 1.98 Billion EUR | 10.66% |
| 2005 | 1.79 Billion EUR | -31.28% |
| 2004 | 2.6 Billion EUR | 8.7% |
| 2003 | 2.39 Billion EUR | -24.58% |
| 2002 | 3.17 Billion EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.94 Billion EUR | 0.0% |
| 2023 Q2 | 1.68 Billion EUR | 0.0% |
| 2023 FY | 3.34 Billion EUR | -8.54% |
| 2023 Q4 | 1.65 Billion EUR | 0.0% |
| 2022 FY | 3.65 Billion EUR | -12.27% |
| 2022 Q2 | 1.98 Billion EUR | 0.0% |
| 2022 Q4 | 1.66 Billion EUR | 0.0% |
| 2021 Q2 | 2 Billion EUR | 0.0% |
| 2021 FY | 4.16 Billion EUR | 9.35% |
| 2021 Q4 | 2.16 Billion EUR | 0.0% |
| 2020 FY | 3.8 Billion EUR | 9.27% |
| 2020 Q4 | 1.96 Billion EUR | 0.0% |
| 2020 Q2 | 1.84 Billion EUR | 0.0% |
| 2019 Q4 | 1.84 Billion EUR | 0.0% |
| 2019 FY | 3.48 Billion EUR | 1.51% |
| 2019 Q2 | 1.64 Billion EUR | 0.0% |
| 2018 Q2 | 1.69 Billion EUR | 0.0% |
| 2018 FY | 3.43 Billion EUR | 4.89% |
| 2017 Q4 | 1.66 Billion EUR | 0.0% |
| 2017 FY | 3.27 Billion EUR | 11.17% |
| 2017 Q2 | 1.61 Billion EUR | 0.0% |
| 2016 FY | 2.94 Billion EUR | 8.31% |
| 2016 Q2 | 1.42 Billion EUR | 0.0% |
| 2015 FY | 2.71 Billion EUR | 18.68% |
| 2015 Q4 | 1.35 Billion EUR | 0.0% |
| 2015 Q2 | 1.36 Billion EUR | 0.0% |
| 2014 Q4 | 1.18 Billion EUR | 0.0% |
| 2014 FY | 2.29 Billion EUR | 5.67% |
| 2014 Q2 | 1.1 Billion EUR | 0.0% |
| 2013 Q4 | 1.02 Billion EUR | 0.0% |
| 2013 Q2 | 1.13 Billion EUR | 0.0% |
| 2013 FY | 2.16 Billion EUR | -8.83% |
| 2012 Q3 | 594.5 Million EUR | 0.0% |
| 2012 FY | 2.37 Billion EUR | 6.49% |
| 2012 Q4 | 574.25 Million EUR | -3.41% |
| 2012 Q2 | 594.5 Million EUR | 0.0% |
| 2012 Q1 | 594.5 Million EUR | 0.0% |
| 2011 Q1 | 558.25 Million EUR | 0.0% |
| 2011 Q2 | 558.25 Million EUR | 0.0% |
| 2011 Q3 | 558.25 Million EUR | 0.0% |
| 2011 Q4 | 594.5 Million EUR | 6.49% |
| 2011 FY | 2.23 Billion EUR | 3.14% |
| 2010 Q4 | 558.25 Million EUR | 3.14% |
| 2010 Q2 | 541.25 Million EUR | 0.0% |
| 2010 Q3 | 541.25 Million EUR | 0.0% |
| 2010 Q1 | 541.25 Million EUR | 0.0% |
| 2010 FY | 2.16 Billion EUR | 3.54% |
| 2009 Q4 | 541.25 Million EUR | 3.54% |
| 2009 FY | 2.09 Billion EUR | -14.83% |
| 2009 Q2 | 522.75 Million EUR | 0.0% |
| 2009 Q3 | 522.75 Million EUR | 0.0% |
| 2009 Q1 | 522.75 Million EUR | 0.0% |
| 2008 Q3 | 613.75 Million EUR | 0.0% |
| 2008 FY | 2.45 Billion EUR | -4.81% |
| 2008 Q1 | 613.75 Million EUR | 0.0% |
| 2008 Q2 | 613.75 Million EUR | 0.0% |
| 2008 Q4 | 522.75 Million EUR | -14.83% |
| 2007 Q4 | 613.75 Million EUR | -4.81% |
| 2007 FY | 2.57 Billion EUR | 30.12% |
| 2007 Q3 | 644.75 Million EUR | 0.0% |
| 2007 Q2 | 644.75 Million EUR | 0.0% |
| 2007 Q1 | 644.75 Million EUR | 0.0% |
| 2006 Q3 | 495.5 Million EUR | 0.0% |
| 2006 Q4 | 644.75 Million EUR | 30.12% |
| 2006 Q2 | 495.5 Million EUR | 0.0% |
| 2006 FY | 1.98 Billion EUR | 10.66% |
| 2006 Q1 | 495.5 Million EUR | 0.0% |
| 2005 Q4 | 495.5 Million EUR | 10.66% |
| 2005 FY | 1.79 Billion EUR | -31.28% |
| 2005 Q2 | 447.75 Million EUR | 0.0% |
| 2005 Q3 | 447.75 Million EUR | 0.0% |
| 2005 Q1 | 447.75 Million EUR | 0.0% |
| 2004 Q2 | 651.58 Million EUR | 0.0% |
| 2004 FY | 2.6 Billion EUR | 8.7% |
| 2004 Q1 | 651.58 Million EUR | 0.0% |
| 2004 Q3 | 651.58 Million EUR | 0.0% |
| 2004 Q4 | 447.75 Million EUR | -31.28% |
| 2003 Q4 | 651.58 Million EUR | 8.7% |
| 2003 Q3 | 599.4 Million EUR | 0.0% |
| 2003 Q1 | 599.4 Million EUR | 0.0% |
| 2003 Q2 | 599.4 Million EUR | 0.0% |
| 2003 FY | 2.39 Billion EUR | -24.58% |
| 2002 Q3 | 794.77 Million EUR | 0.0% |
| 2002 Q2 | 794.77 Million EUR | 0.0% |
| 2002 Q1 | 794.77 Million EUR | 0.0% |
| 2002 FY | 3.17 Billion EUR | 0.0% |
| 2002 Q4 | 599.4 Million EUR | -24.58% |
| 2001 Q4 | 794.77 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -540676.699% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -85285.795% |
| Adocia SA | 1.38 Million EUR | -241199.639% |
| Aelis Farma SA | 12.35 Million EUR | -26943.211% |
| Biophytis S.A. | -803 Thousand EUR | 416289.29% |
| Advicenne S.A. | 1.42 Million EUR | -234261.851% |
| genOway Société anonyme | 20.1 Million EUR | -16526.55% |
| IntegraGen SA | 5.01 Million EUR | -66496.523% |
| Medesis Pharma S.A. | -2.66 Million EUR | 125514.295% |
| Neovacs S.A. | 29.31 Thousand EUR | -11400595.913% |
| NFL Biosciences SA | -56.06 Thousand EUR | 5961144.521% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -155131.251% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 235570.014% |
| Sensorion SA | 3.78 Million EUR | -88129.191% |
| Theranexus Société Anonyme | -4.63 Million EUR | 72146.203% |
| TME Pharma N.V. | -127 Thousand EUR | 2631596.063% |
| Valbiotis SA | 2.66 Million EUR | -125162.369% |
| TheraVet SA | -530.79 Thousand EUR | 629720.419% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -263672.691% |
| argenx SE | 925.49 Million EUR | -261.103% |
| BioSenic S.A. | 543 Thousand EUR | -615369.613% |
| Celyad Oncology SA | 33 Thousand EUR | -10127172.727% |
| DBV Technologies S.A. | 4.15 Million EUR | -80244.418% |
| Galapagos NV | 203.73 Million EUR | -1540.366% |
| Genfit S.A. | 28.22 Million EUR | -11740.986% |
| GeNeuro SA | -293.8 Thousand EUR | 1137608.509% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | -167502.808% |
| Innate Pharma S.A. | -4.12 Million EUR | 81196.821% |
| Inventiva S.A. | 17.5 Million EUR | -18997.143% |
| MaaT Pharma SA | 1.65 Million EUR | -201833.535% |
| MedinCell S.A. | 9.28 Million EUR | -35881.912% |
| Nanobiotix S.A. | 36.2 Million EUR | -9130.004% |
| Onward Medical N.V. | -14.81 Million EUR | 22653.651% |
| Oryzon Genomics S.A. | 13.94 Million EUR | -23860.572% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -149967.355% |
| Oxurion NV | 104 Thousand EUR | -3213361.538% |
| Pharming Group N.V. | 220.1 Million EUR | -1418.373% |
| Poxel S.A. | 1000.00 EUR | -334199900.0% |
| GenSight Biologics S.A. | 3 Million EUR | -111300.0% |
| Transgene SA | -28.4 Million EUR | 11865.948% |
| Financière de Tubize SA | -2.02 Million EUR | 164764.205% |
| Valneva SE | 52.83 Million EUR | -6225.113% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 108080.614% |